Alzamend Neuro, Inc. (ALZN) Stock Forecast
ALZN analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $26.00 average of analyst targets
- Upside to target
- +1,900.0% from the latest close
- Next earnings
- December 8, 2026 EPS estimate $-0.23
- 52-week range
- $0.86 – $2.61
ALZN analyst ratings
1 analystsNumber of analysts at each rating.
ALZN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ALZN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Oct '26) | −$0.23 | −$0.23 | −$0.23 | −$0.30 | +23.3% | 1 |
| Next quarter (Jan '27) | −$0.22 | −$0.22 | −$0.22 | −$0.58 | +62.1% | 1 |
| Current fiscal year (FY2027) | −$1.05 | −$1.05 | −$1.05 | −$2.63 | +60.1% | 1 |
| Next fiscal year (FY2028) | −$0.87 | −$0.87 | −$0.87 | −$1.05 | +17.1% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ALZN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Oct '26) | $0 | $0 | $0 | 0.0% | 1 |
| Next quarter (Jan '27) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (FY2027) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (FY2028) | $0 | $0 | $0 | 0.0% | 1 |
ALZN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ALZN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Oct '26) | −$0.66 | −$0.66 | −$0.66 | −$0.66 | −$0.23 | −65.2% | 1 up · 0 down |
| Next quarter (Jan '27) | −$0.64 | −$0.64 | −$0.64 | −$0.64 | −$0.22 | −65.6% | 1 up · 0 down |
| Current fiscal year (FY2027) | −$2.60 | −$2.60 | −$2.60 | −$2.60 | −$1.05 | −59.6% | 1 up · 0 down |
| Next fiscal year (FY2028) | $0.00 | $0.00 | $0.00 | $0.00 | −$0.87 | — | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ALZN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ALZN beat in 4 of 12.
What analysts expect from ALZN
1 analysts cover Alzamend Neuro; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $26.00, 1,900.0% above the latest close of $1.30. Analysts expect earnings of −$1.05 per share for FY2027, +60.1% from a year earlier. For FY2028 the average estimate is −$0.87 per share. Alzamend Neuro beat the EPS estimate in 4 of the last 12 quarters.
Related: ALZN income statement, ALZN key metrics, ALZN chart. See the ALZN stock overview for the latest quote and news.
ALZN forecast FAQ
What is Alzamend Neuro's price target?
The average analyst price target for Alzamend Neuro is $26.00, 1,900.0% above the latest close of $1.30.
Is Alzamend Neuro a buy, hold or sell?
Of 1 analysts covering Alzamend Neuro, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Alzamend Neuro's EPS forecast?
Analysts forecast −$1.05 per share for FY2027 (range −$1.05 to −$1.05); for FY2028 the estimate is −$0.87.
When does Alzamend Neuro report earnings?
Alzamend Neuro is expected to report results for the quarter ending October 31, 2026 on December 8, 2026; the EPS estimate is $-0.23.
Does Alzamend Neuro usually beat earnings estimates?
Alzamend Neuro reported EPS at or above the analyst estimate in 4 of the last 12 quarters.